详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. [2]Peking University Fifth School of Clinical Medicine, Beijing, China.

出处：

DOI：

关键词： Immune checkpoint inhibitors (ICIs) Vogt-Koyanagi-Harada disease (VKHD)-like uveitis Immune-related adverse events (irAEs) Anti-PD-1 (Toripalimab)

摘要：

Several immune checkpoint inhibitors (ICIs) have been linked to the occurrence of Vogt-Koyanagi-Harada disease (VKHD)-like uveitis. Among the ICIs, there has been no report of immune-related adverse events (irAEs) caused by a new programmed death protein-1(PD-1) monoclonal antibody (Toripalimab).This paper presents a case of VKHD-like uveitis that arose following Toripalimab therapy for urothelial cancer of the bladder, and the patient experienced symptoms 10 days after the final dosage of 20 months of medication treatment. This patient with bladder uroepithelial carcinoma had severe binocular acute panuveitis with exudative retinal detachment after receiving Toripalimab therapy. Binocular VKHD-like uveitis was suggested as a diagnosis. Both eyes recovered after discontinuing immune checkpoint inhibitors and local and systemic corticosteroid treatment.This report suggests that VKHD-like uveitis can also occur in patients receiving novel PD-1 antibodies and the importance of paying attention to eye complications in patients receiving treatment over a long period.© 2024. The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 3 区眼科学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区眼科学

第一作者：

第一作者机构： [1]Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China. [2]Peking University Fifth School of Clinical Medicine, Beijing, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Phase II Clinical Trial of Neoadjuvant anti-PD-1 (Toripalimab) Combined with Axitinib in Resectable Mucosal Melanoma [2]Bilateral retrobulbar optic neuritis combined with optic perineuritis associated with atezolizumab treatment for small cell lung carcinoma [3]Glaucomatous Injury of Central Nerve System [4]患高血压冬天护好三部位 [5]前列腺等离子剜切术和钬激光剜除术治疗良性前列腺增生疗效分析 [6]萎缩型老年性黄斑变性患眼地图样萎缩面积的多模态成像定量分析 [7]苯扎托品对大鼠非动脉炎性前部缺血性视神经病变模型神经保护作用初探 [8]甲状腺肿瘤的常见手术方式及icd-9-cm-3编码解析 [9]Observation of fundus and optical coherence tomography angiography manifestations in carotid cavernous fistula patients [10]